share_log

S-3: Registration statement for specified transactions by certain issuers

S-3: Registration statement for specified transactions by certain issuers

S-3:特定交易注册声明
美股SEC公告 ·  2024/11/26 06:12

Moomoo AI 已提取核心信息

On November 25, 2024, Conduit Pharmaceuticals filed a Form S-3 registration statement with the SEC to register 75 million shares of common stock for resale by Nirland Limited. These shares may be issued upon the conversion of the August 2024 Senior Secured Promissory Note. Conduit will not receive any proceeds from the sale of these shares.The shares are being registered to allow Nirland Limited, the selling stockholder, to offer and sell them from time to time. The shares may be sold at market prices, prices related to market prices, or privately negotiated prices. Conduit's common stock is traded on Nasdaq under the symbol "CDT."This registration is part of Conduit's strategy to manage its financial obligations and provide liquidity options for its stakeholders. Investors are advised to consider the associated risks detailed in the prospectus.
On November 25, 2024, Conduit Pharmaceuticals filed a Form S-3 registration statement with the SEC to register 75 million shares of common stock for resale by Nirland Limited. These shares may be issued upon the conversion of the August 2024 Senior Secured Promissory Note. Conduit will not receive any proceeds from the sale of these shares.The shares are being registered to allow Nirland Limited, the selling stockholder, to offer and sell them from time to time. The shares may be sold at market prices, prices related to market prices, or privately negotiated prices. Conduit's common stock is traded on Nasdaq under the symbol "CDT."This registration is part of Conduit's strategy to manage its financial obligations and provide liquidity options for its stakeholders. Investors are advised to consider the associated risks detailed in the prospectus.
2024年11月25日,Conduit Pharmicals向美国证券交易委员会提交了S-3表格注册声明,要求注册7500万股普通股供Nirland Limited转售。这些股票可以在2024年8月优先担保本票转换后发行。Conduit 不会从出售这些股票中获得任何收益。正在注册这些股票,以允许出售股东Nirland Limited不时发行和出售。股票可以按市场价格、与市场价格相关的价格或私下议定的价格出售。Conduit的普通股在纳斯达克上市,股票代码为 “cdT”。此次注册是Conduit管理其财务义务并为其利益相关者提供流动性选择的战略的一部分。建议投资者考虑招股说明书中详述的相关风险。
2024年11月25日,Conduit Pharmicals向美国证券交易委员会提交了S-3表格注册声明,要求注册7500万股普通股供Nirland Limited转售。这些股票可以在2024年8月优先担保本票转换后发行。Conduit 不会从出售这些股票中获得任何收益。正在注册这些股票,以允许出售股东Nirland Limited不时发行和出售。股票可以按市场价格、与市场价格相关的价格或私下议定的价格出售。Conduit的普通股在纳斯达克上市,股票代码为 “cdT”。此次注册是Conduit管理其财务义务并为其利益相关者提供流动性选择的战略的一部分。建议投资者考虑招股说明书中详述的相关风险。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息